Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Vaccinations01:51

Vaccinations

Overview
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cuproptosis-inducing photothermal nanotherapy coupled with ECM destabilization drives potent tumor regression and immune reawakening.

Materials today. Bio·2026
Same author

KITENIN-CCL20 axis is a potential therapeutic target for modulating immunosuppressive tumor microenvironment in glioblastoma.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1.

NPJ vaccines·2026
Same author

Brain metastasis-associated cancer fibroblasts drive tumor progression and therapeutic resistance through IL26 and CX3CL1 signaling in non-small-cell lung cancer.

Experimental hematology & oncology·2025
Same author

Restoration of Oxacillin susceptibility in MRSA strains by NPPB.

Scientific reports·2025
Same author

Protein nanocages: A new frontier in mucosal vaccine delivery and immune activation.

Human vaccines & immunotherapeutics·2025

Related Experiment Video

Updated: May 12, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Mucosal vaccine adjuvants update.

Joon Haeng Rhee1, Shee Eun Lee, Soo Young Kim

  • 1Clinical Vaccine R&D Center, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. ; Department of Microbiology and Research Institute of Vibrio Infections, Chonnam National University Medical School, Gwangju, Korea.

Clinical and Experimental Vaccine Research
|April 19, 2013
PubMed
Summary

Mucosal vaccines offer advantages like needle-free delivery and pandemic preparedness. Recent advances in innate immunity are driving the development of new mucosal adjuvants for improved vaccine efficacy.

Keywords:
AdjuvantInnate immunityMucosalVaccine

More Related Videos

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Related Experiment Videos

Last Updated: May 12, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Disease Research

Background:

  • Mucosal vaccination elicits both mucosal and systemic immunity, presenting significant advantages for vaccine development.
  • Current limitations in approved mucosal vaccines highlight the need for effective adjuvant strategies.
  • Mucosal vaccines offer benefits such as lower cost, needle-free administration, and scalability for mass immunization.

Purpose of the Study:

  • To review recent advancements in mucosal adjuvants and their role in vaccine development.
  • To explore the interplay between innate immunity and mucosal immune responses.
  • To discuss basic and applied research in mucosal adjuvant discovery.

Main Methods:

  • Literature review focusing on innate immunity, mucosal immunity, and adjuvant development.
  • Analysis of recent scientific achievements translated into novel adjuvant strategies.
  • Synthesis of current understanding and future directions in mucosal adjuvant research.

Main Results:

  • Fundamental scientific breakthroughs in innate immunity are enabling the development of novel mucosal adjuvants.
  • Adjuvant research is shifting from empirical approaches to science-driven strategies.
  • Emerging mucosal adjuvants hold promise for enhancing vaccine efficacy and broadening applicability.

Conclusions:

  • The development of effective mucosal adjuvants is critical for realizing the full potential of mucosal vaccines.
  • Continued research integrating innate immunity principles is key to advancing mucosal adjuvant technology.
  • Mucosal vaccines, supported by innovative adjuvants, represent a promising frontier in the vaccine industry.